In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. James R. Berenson argues that myeloma patients should be maintained with proteasome inhibitors.
A continuing education program is offered as a supplement to this webcast at the following location:
http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP
© 2016 Imedex, LLC.
Advertisement